MedElevator
Войти в исследования Transactions of the Royal Society of Tropical Medicine and Hygiene · 2026
Epidemiological insights into the co-circulation of Zika and dengue viruses in Yangon, Myanmar (2017-2019).
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mutua Maurine Mumo, Ngwe Tun Mya Myat, Nwe Khine Mya, Lin Htin, Kapandji Merveille, Inoue Shingo, Thant Kyaw Zin, Takamatsu Yuki, Aung Wah Wah, Khin Aye Aye, Thu Hlaing Myat, Urano Takeshi, Morita Kouichi
Аннотация
BACKGROUND: Zika virus (ZIKV) is a mosquito-borne flavivirus mainly transmitted by Aedes aegypti and Aedes albopictus. While well-studied in the Americas, data from Southeast Asia, especially Myanmar, remain limited. This study assessed ZIKV infection among dengue-suspected patients in Yangon, Myanmar, from 2017 to 2019.
METHODS: This was a cross-sectional retrospective study that collected serum samples from 1162 clinically dengue-suspected patients. Reverse transcription quantitative polymerase chain reaction (RT-qPCR) was used to detect ZIKV RNA and serological assays were used to identify ZIKV-specific immunoglobulin M (IgM), IgG and neutralizing antibodies. The age, gender, clinical manifestations and coinfections with dengue virus (DENV) were determined.
RESULTS: Of the 1162 samples, 23 (2.0%) were positive for ZIKV by RT-qPCR. Among these, nine samples showed coinfection with DENV: four with DENV-1, two with DENV-3 and three with DENV-4. Of the 111 (9.6%) samples that tested positive for ZIKV IgM, 11 (9.9%) had neutralizing antibodies against ZIKV, with 9 (8.1%) confirmed as ZIKV positive and 2 (1.8%) classified as probable cases.
CONCLUSIONS: Our study reported that 32 cases (2.8%) were confirmed as ZIKV infections by molecular and serological detection. The findings underscore the need for improved surveillance, diagnostic accuracy and public health interventions to mitigate the impact of ZIKV.
METHODS: This was a cross-sectional retrospective study that collected serum samples from 1162 clinically dengue-suspected patients. Reverse transcription quantitative polymerase chain reaction (RT-qPCR) was used to detect ZIKV RNA and serological assays were used to identify ZIKV-specific immunoglobulin M (IgM), IgG and neutralizing antibodies. The age, gender, clinical manifestations and coinfections with dengue virus (DENV) were determined.
RESULTS: Of the 1162 samples, 23 (2.0%) were positive for ZIKV by RT-qPCR. Among these, nine samples showed coinfection with DENV: four with DENV-1, two with DENV-3 and three with DENV-4. Of the 111 (9.6%) samples that tested positive for ZIKV IgM, 11 (9.9%) had neutralizing antibodies against ZIKV, with 9 (8.1%) confirmed as ZIKV positive and 2 (1.8%) classified as probable cases.
CONCLUSIONS: Our study reported that 32 cases (2.8%) were confirmed as ZIKV infections by molecular and serological detection. The findings underscore the need for improved surveillance, diagnostic accuracy and public health interventions to mitigate the impact of ZIKV.